Patents by Inventor Anders Bjartell

Anders Bjartell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ether analogues of galiellalactone
    Patent number: 10351577
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 16, 2019
    Assignee: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • ETHER ANALOGUES OF GALIELLALACTONE
    Publication number: 20180155360
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Application
    Filed: June 2, 2016
    Publication date: June 7, 2018
    Applicant: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
    Patent number: 9278119
    Abstract: The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: March 8, 2016
    Assignee: WNTRESEARCH AB
    Inventors: Tommy Andersson, Anders Bjartell
  • TREATMENT OF PROSTATE CANCER AND A METHOD FOR DETERMINING THE PROGNOSIS FOR PROSTATE CANCER PATIENTS
    Publication number: 20140206623
    Abstract: The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.
    Type: Application
    Filed: June 28, 2012
    Publication date: July 24, 2014
    Applicant: WNTRESEARCH AB
    Inventors: Tommy Andersson, Anders Bjartell